The first crystal structure of a broadly active antibody against surface glycoproteins of ebolaviruses identifies a highly conserved epitope beneath the glycan cap and highlights the molecular requirements for broad ebolavirus neutralization.
The heavy and light chains each contribute roughly half of the overall ADI-15946 binding interface: ~55% from the heavy chain (HC) complementarity-determining region 3 (CDR H3), and the remaining 45% from the combined contributions of the light chain (LC) framework region 3 (FRL3) and CDRs 1, 2, and 3 (L1, L2, and L3 respectively) ( Fig. 1B-C) .
Notably, CDRs 1 and 2 of the heavy chain (H1 and H2, respectively) do not participate in the Fab-GP CL interface ( Fig. 1B-C) . Instead, HC recognition of GP CL is mediated exclusively by the 22-amino-acid-long CDR H3 which buries approximately 465 Å 2 of surface area upon binding ( Fig. 1B) . ADI-15946 HC contacts include the strictly conserved lysine at position 510 in the GP 2 N terminus-where a substitution to glutamic acid, K510E, was previously shown to give rise to escape from viral neutralization (9) . Our sidechain modeling suggests that the K510E substitution may introduce a charged/steric clash with residues D100 C and/or L100 F of CDR H3 thereby explaining the loss of antiviral activity (Fig. S1 ). The left boundary of ADI-15946's footprint, formed by LC FRL3, is in immediate proximity to the β13-β14 loop that passes over the IFL and is cleaved by endosomal cathepsins during viral entry ( Fig. S2) (12, 13) . Overlay of our structure with uncleaved GP (PDB: 5JQ3) shows that ADI-15946 binding likely impedes protease access to this loop, which is consistent with previously reported ADI-15946 inhibition of GP proteolysis ( Fig. S2) (9) .
The bottom of ADI-15946's footprint partially overlaps those of the EBOV-monospecific binders KZ52, 2G4 and 4G7 ( Fig. S3) (2, 20) . However, ADI-15946 likely gains cross-reactivity from an upward shift of its footprint which allows it to target a highly conserved pocket above the upper boundary of the KZ52 epitope as suggested previously (Fig. 3F, S3 , and S4) (9) . This pocket is formed by residues 71-75 of GP 1 , which fold into a 3 10 helix, and is hereafter termed the '3 10 pocket' (Fig. 2A) . The 3 10 helix rearranges in GP CL when bound to NPC1, and stabilization of this region by ADI-15946 CDR H3 may be part of the mAb's neutralization mechanism ( Fig. S4) (8, 9, 15) .
In uncleaved GP, the 3 10 pocket is occupied by the β17-β18 loop (GP 1 residues 287-291) that extends down from the glycan cap ( Fig. 2A and S4) (8, 21) . Interactions of ADI-15946 CDR H3 residues D100 C , W100 D , and L100 E with the 3 10 pocket mimic the contacts made by β17-β18 loop residues E292, W291, and F290, respectively ( Fig. 2A) . Correspondingly, we postulated that the viral β17-β18 loop peptide competes for binding with CDR H3 of ADI-15946 in full length GP (GP FL ) ( Fig. 2A, S4 , and S5). To test the effect of β17-β18 loop removal on ADI-15946 binding and neutralization, we measured the apparent binding constant (K D app ) for ADI-15946 interaction with EBOV GP FL and GP CL via Bio-Layer Interferometry (BLI) and its neutralization of recombinant vesicular stomatitis virus (rVSV) particles bearing EBOV GP FL and GP CL (rVSV-EBOV GP FL and rVSV EBOV GP CL , respectively). We observed a 10,000-fold improvement in binding and a 100-fold improvement in neutralization potency against EBOV GP CL compared to full-length GP (Fig. 2C , 3D-E, and Tables S2 and S4 ). Comparison of association (k on ) and dissociation (k off ) rates of ADI-15946 to EBOV GP FL and GP CL showed that the improved binding to GP CL is primarily driven by over 1000-fold slower k off and a modest improvement of the association rate (10-fold increased k on ) ( Fig. 2D , S16 and table S2). Given the sizeable contribution of CDR H3 to the binding interface, the slower dissociation rate against GP CL likely results from its unobstructed access to the 3 10 pocket.
To specifically probe the importance of the β17-β18 loop's hydrophobic packing into the 3 10 pocket to the shielding of the ADI-15946 epitope, we tested ADI-15946 binding and neutralization against rVSVs bearing an EBOV GP variant with an arginine substitution at position 291 (rVSV-EBOV GP W291R ). Modeling of the arginine sidechain suggested that the W291R substitution would displace the β17-β18 loop from the conserved pocket by introducing charged and steric clashes with the GP 2 residue asparagine 512 ( Fig. S6 ). Consistent with this hypothesis, we observed a 10-fold enhancement in ADI-15946 binding to EBOV GP W291R compared to wild-type EBOV GP (GP WT ) presented on rVSV and a >10-fold increase in neutralization efficiency of rVSV bearing EBOV GP W291R relative to EBOV GP WT ( Fig. 2B-C) .
The intermediate neutralization potency of rVSV-EBOV GP W291R compared to GP CL and GP WT , suggests that displacement of the β17-β18 loop from the 3 10 pocket is the limiting factor for binding of ADI-15946 to EBOV GP ( Fig. 2C ).
Previous work suggests that a non-neutralizing mAb, FVM09, recognizes and "peels away" the β17-β18 loop from the base, thereby enhancing neutralization by the base-binding mAb 2G4 (22, 23) . Given the more profound role of the β17-β18 loop in restricting access of ADI-15946 to its base epitope (see above), we evaluated the hypothesis that FVM09 could also work in concert with ADI-15946 to neutralize virus. We first tested competition between ADI-15946 and FVM09 using BLI-based competitive binding assays and found that both mAbs could bind to EBOV GP simultaneously ( Fig. S7 ). We next tested the effect of FVM09 on ADI-15946 neutralization of rVSV-EBOV GP or authentic EBOV in the presence of three fixed concentrations of FVM09. FVM09 potentiated ADI-15946 neutralization in a concentrationdependent manner by >10-fold, but had no effect on neutralization by KZ52 ( Fig. 2E ).
Conversely, titration of FVM09 into a constant, sub-neutralizing concentration of ADI-15946 also showed dose-dependent enhancement of ADI-15946 neutralizing activity ( Fig. 2F ). In contrast, KZ52 neutralization was somewhat reduced in the same assay, perhaps because KZ52 binds along the surface of the β17-β18 loop whereas ADI-15946 binds beneath the β17-β18 loop ( Fig. 2F , S8 and S9). We observed similar neutralization enhancement trends with authentic EBOV ( Fig. S9A-B ), and to a lesser extent, with rVSV-SUDV GP ( Fig. S9C-D) . The functional significance of the strict conservation of the amino acid sequence in the 3 10 pocket and the β17-β18 loop among ebolavirus GPs remains unknown, but it may relate to the transduction of conformational changes in GP upon NPC1 binding (8) . Our results demonstrate that rare neutralizing antibodies like ADI-15946 can access and exploit this site for broad ebolavirus neutralization, presumably by neutralizing its functional role in viral entry. The enhancement of ADI-15946 binding and neutralization in the presence of β17-β18 loop binders such as FVM09 may reflect a mechanism by which specific combinations of glycan cap-and base-binding mAbs can synergize to interdict viral infection during a natural polyclonal immune response.
To delineate the molecular basis of ADI-15946's broad activity, we assigned its light and heavy chain variable domain (VL and VH, respectively) sequences to their most probable inferred germline progenitors (IGL) (Fig. 3A ). We found that reversion of three residues introduced by somatic hypermutation (SHM) in the VH to germline (LC WT :HC IGL ; CDR H3 is retained fully mature) had no appreciable impact on binding of full-length or cleaved EBOV, BDBV, or SUDV GP or neutralization of rVSV bearing EBOV, BDBV, or SUDV GP ( Fig. 3D -E, and Fig. S10 ). These findings agree with our structural observations, since only CDR H3 participates in binding to EBOV GP CL ( Fig. 1B-C ). The structure also suggests that the length of CDR H3 is critical for the mAb's ability to access the 3 10 pocket. We tested three truncation mutants of ADI-15946 CDR H3 and found complete loss of binding and neutralization with all three (Fig. S11 ).
Reversion of ten SHM-introduced residues in the VL outside of CDR L3 (LC IGL :HC WT ; residues 3, 4, 27, 28, 31, 53, 67, 72, 87, 104) had a profound impact on neutralization of rVSVs bearing EBOV, BDBV, or SUDV GP ( Fig. 3A, and S9 ). Both the LC IGL :HC WT and the combined LC IGL :HC IGL Ab variants were non-neutralizing against rVSV-EBOV GP FL despite retaining a fully mature CDR H3 and CDR L3, suggesting that LC contacts outside of CDR L3 make key contributions to GP recognition (Fig. 3E ). The LC IGL :HC WT and the LC IGL :HC IGL germlineapproximating Ab variants retained some neutralizing activity against EBOV GP CL and BDBV GP CL, likely due to improved access of CDR H3 to the 3 10 pocket ( Fig. 3E , and Table S2 ).
However LC IGL :HC IGL did not neutralize rVSV-SUDV GP CL , probably due to clashes between ADI-15946 CDR H3 and residues in the N-terminal tail of SUDV GP 2 (Fig. S10 ). Our germlineapproximating variants LC IGL :HC WT and the LC IGL :HC IGL neutralized the rVSV-EBOV GP W291R variant more potently than rVSV-EBOV GP CL which suggests that additional LC contacts that are absent in GP CL , likely between the Ab and the glycan cap, contribute to ADI-15946's activity against GP FL (Fig. S2 , S10G and Table S2 ).
Our analysis of ADI-15946's epitope conservation shows that the limited SUDV reactivity and lack of activity against Reston virus (RESTV) likely arise from the amino acid sequence divergence on the edges of its footprint (Fig 3F, S12 , and S13). There are only five non-conserved residues across all five ebolavirus GPs involved in the interface with ADI-15946, all located in GP 2 : N506, N514, H516, L547, and H549 ( Fig. 3F and Fig. S12 ). These are predominantly contacted by CDR L2 and FRL3 ( Fig. S12 ). However, CDR H3 contacts one key residue in EBOV GP (Asn 506) that is not conserved in SUDV GP (Arg 506). Using this information, we separately mutated nearby residues in ADI-15946 CDR H3, R100 and Y100 A , to alanine to reduce steric and charge clashes with SUDV R506. The ADI-15946 mutant Y100 A showed decreased binding to both SUDV and BDBV GP compared to wild-type ADI-15946 ( Fig   S14) . However, the mAb variant called 46M1, containing R100A, showed increased binding to SUDV GP ectodomain by ELISA and slightly improved neutralization of authentic virus compared to the parental antibody ( Fig. 4E -L and S13 ).
Structural alignment of additional Fab-GP complexes enabled comparison of the binding features of ADI-15946 with monospecific mAbs KZ52 and c4G7, which share part of their footprints with ADI-15946. (Fig. S3 , S8, and S15) (2, 20) . We observed that the HC of c4G7 places a tyrosine residue in a similar position and orientation to that of the ADI-15946 LC residue F67 and another tyrosine residue proximal to ADI-15946 LC residue S65 ( Fig. S15 ). We then attempted to mimic this double tyrosine motif by incorporation of light chain S65Y and No high-resolution structure of a broadly neutralizing antibody in complex with an ebolavirus glycoprotein has yet been reported. The crystal structure of ADI-15946 Fab in complex with EBOV GP CL and accompanying biochemistry presented here illuminate antigenic features of GP that dictate access to a broadly conserved but previously unappreciated epitope shared by ebolaviruses. This site of vulnerability is shielded by the descending β17-β18 loop of the glycan cap, removal of which potentiates ADI-15946 activity. We also uncover potentially synergistic neutralization between ADI-15946 and the non-neutralizing glycan cap binder FVM09. Our findings support a mechanism of action whereby ADI-15946 gains enhanced neutralizing activity against the endosomal, cleaved viral GP species generated by host proteases during entry. In contrast, other potent neutralizers that target the GP base, such as KZ52 and the ZMapp components c2G4 and c4G7, have been shown to lose their activity against GP CL (9) .
The mechanism of neutralization by ADI-15946 may also involve inhibition of conformational changes required for membrane fusion by anchoring to the GP 1 -GP 2 interface across the IFL thereby preventing its unraveling from the GP 1 core during fusion triggering. In addition, binding of ADI-15946 in the 3 10 pocket could prevent rearrangement of GP 1 residues 71-75 upon binding of GP CL to NPC1 by mimicking the hydrophobic interactions of the β17-β18 loop that packs into the pocket in GP FL (Fig. S4 ) (8) . Rational structure-guided substitutions, two in the LC FRL3 and one in CDR H3, enhanced both binding and neutralization activity against SUDV without loss of activity against EBOV or BDBV.
Analysis of germline-reverted versions of the antibody indicated that a limited number of somatic mutations were required to bind this conserved GP site and that many of these mutations occurred in the framework region. Klein et al. show that somatic mutations in the immunoglobulin framework region enhance affinity by decreasing the dissociation rate and are generally necessary to achieve broad neutralization of HIV-1 (25) . We found that, similar to broadly neutralizing antibodies against HIV-1, ADI-15946 also required somatic maturation of the framework region, which decreased its dissociation rate, in order to achieve broad neutralization of ebolaviruses (25) .
Our work details structural features of GP recognized by a broadly active anti-ebolavirus antibody and provides specific strategies (i.e. cleaving GP to remove the glycan cap or recombinantly expressing a Δβ17-β18 loop variant of GP) to enable the targeting of a highly conserved site in the design of vaccines and immunotherapeutics. The structure also provided the roadmap for rational engineering of the parent Ab to enhance its activity against Sudan virus.
The resulting broadly neutralizing antibody may be suitable as a component of a protective cocktail targeting the three ebolaviruses known to cause human disease outbreaks. flash frozen in liquid nitrogen for storage and shipping. Diffraction data was collected remotely on SSRL beamline 12-2 on a pilatus 6M detector (26) (27) (28) (29) . Data was processed using XDS (30, 31) , and the structure was determined using molecular replacement with PHASER (32), within the CCP4 suite (33), using the structure of EBOV GP CL (PDB: 5HJ3) as an initial search model (15) . Iterative rounds of model building were performed using Coot (34) , and each round was refined with Phenix (35) . Five percent of the data was set aside prior to refinement for the R free calculations for each data set (36) . The statistics and stereochemistry of the crystal structure were checked using the MolProbity server (36, 37) . Structural figures were rendered using Open Source PyMOL (PyMOL Molecular Graphics System, version 1.7.0.0; Schrödinger, LLC).
Structural Alignment and Visualization of Ebolavirus Glycoproteins
Alignment was performed using clustalomega on uniprot with the following protein sequences: Zaire ebolavirus: Q05320, Bundibugyo ebolavirus: B8XCN0, Sudan ebolavirus: Q66814, Taï Forest ebolavirus: Q66810, Reston ebolavirus: Q66799. Sequence conservation was numbered according to EBOV GP and visualized using the Espript server (http://espript.ibcp.fr) and colored according to the percent equivalent scoring function with a cutoff of 70% (38) .
Anti-GP mAb ELISAs
High-binding 96-well ELISA plates (Corning) were coated with 50 µL GP antigens in phosphate-buffered saline (PBS) at 4 µg/mL, and allowed to bind for 1 h at room temperature. After washing, the wells were blocked with PBS containing 3% bovine serum albumin (PBSA) for 1 h at room temperature, followed by washing then incubation with ADI-15946 or one of its mutant derivatives in serial dilutions of PBS. A horseradish-peroxidase conjugated anti-human secondary antibody (Santa Cruz Biotechnology) was added and allowed to bind for 1 h at room temperature and then subsequently detected by ultra-TMB (3,3′,5,5′-tetramethylbenzidine) substrate (ThermoFisher Scientific). Optical density was measured at 450 nm, and absorbance readings were subjected to a nonlinear regression analysis (GraphPad Prism software) to generate binding curves and calculate an EC 50 value. ELISA assays were performed in triplicate, across seven 5-fold dilutions, beginning at 1000 ng/ml.
Biolayer Interferometry Assays
The Octet Red™ system (FortéBio, Pall) was used to determine the binding properties of different IgGs to various forms of EBOV GP. Anti-human Fc (AHC) capture sensors (ForteBio) were used for initial mAb loading at 25 mg/mL in 1X kinetics buffer (PBS supplemented with 0.002% Tween-20 and 1 mg/mL of BSA). Binding to GP was performed across two-fold serial dilutions of EBOV GPΔTM or GP CL . The baseline and dissociation steps were carried out in the 1X kinetics buffer as per the instrument manufacturer's recommendations. Kinetic binding data in all cases are adequately and accurately described by a 1:1 binding model, but given the bivalent nature of the IgG (immobilized) and the trimeric state of GP (analyte), the association stoichiometry is likely to be more complex. Thus, k off /k on likely reflects an ensemble of binding stoichiometries, and accordingly, we refer to this ratio as apparent K D (K d app ) throughout.
rVSV Neutralization Assays Neutralization of rVSV: Recombinant vesicular stomatitis virus (VSV) expressing both enhanced green fluorescent protein (EGFP) and recombinant surface GP (rVSV-EBOV GP) in place of VSV G are previously described (39) (40) (41) . Vero cells were seeded at 6.0 x 104 cells/well and cultured overnight in Eagle's minimal essential medium (EMEM) supplemented with 10% fetal bovine serum (FBS) and 100 I.U./ml penicillin and 100 mg/ml streptomycin at 37°C and 5% CO 2 . The next day, virus was incubated with serial 3-fold antibody dilutions beginning at 350 nM (~50 µg/ml) in serum free DMEM for one hour at room temperature before infecting Vero cell monolayers in 96-well plates. The virus was incubated with the cells in 50% v/v DMEM supplemented with 2% FBS, 100 I.U./ml penicillin and 100 µg/ml streptomycin at 37 °C and 5% CO 2 for 14-16 hours before the cells were fixed and the nuclei stained with Hoescht. rVSV infectivity was measured by counting EGFP-positive cells in comparison to the total number of cells indicated by nuclear staining using a Cellinsight CX5 automated microscope and accompanying software (ThermoFisher Scientific).
Authentic Virus Neutralization Assays
Neutralization at BSL-4 was tested against replication-competent infectious EGFPexpressing EBOV and chimeric EBOV/BDBV-GP and EBOV/SUDV-GP constructs (referred as EBOV, BDBV and SUDV, respectively) in HTS format, as previously described (42) . The neutralization assays were performed using Vero-E6 cells obtained from ATCC and maintained in Minimal Essential Medium (MEM) (ThermoFisher Scientific) supplemented by 10% fetal bovine serum (HyClone) and 1% penicillin-streptomycin at 5% CO2, 37°C. Neutralization assays were performed in triplicate, across twelve 4-fold dilutions, beginning from 200 µg/ml.
Authentic Virus Cooperativity Assays
The authentic Ebola virus/H.sapiens-tc/COD/1995/Kikwit-9510621 (EBOV/Kik-9510621; 'EBOV-Zaire 1995') (43) , was used in this study. Antibodies were diluted to indicated concentrations in culture media and incubated with EBOV for 1 h. Vero cells were exposed to antibody/virus inoculum at an MOI of 0.2 plaque-forming unit (PFU)/cell for 1 h. Antibody/virus inoculum was then removed and fresh culture media was added. At 48 h post-infection, cells were fixed with formalin, and blocked with 1% bovine serum albumin. EBOV-infected cells and uninfected controls were incubated with EBOV GP-specific mAb KZ52 (44) . Cells were washed with PBS prior to incubation with goat anti-human IgG conjugated to Alexa 488. Cells were counterstained with Hoechst stain (Invitrogen), washed with PBS and stored at 4°C. Infected cells were quantitated by fluorescence microscopy and automated image analysis. Images were acquired at 20 fields/well with a 20× objective lens on an Operetta high content device (Perkin 
e R work = (Σ hkl ǁF obs | − k |F calc ǁ)/(Σ hkl |F obs |). f R free is the same as R work with 5% of reflections chosen at random and omitted from refinement. g RMSD, root mean square deviation. Table S3 . Neutralization potency (IC 50 ) of ADI-15946 variants against authentic filoviruses. Table S4 . Binding kinetics of ADI-15946 compared to inferred germline progenitors. Figure S1 . The K510E escape mutation likely clashes with ADI-15946 CDR H3. (A) Residue K510 of GP 2 binds into a negatively charged pocket created by ADI-15946 CDR H3. Stereo views of the ADI-15946:GP CL complex (ADI-15946 in orange, and GP CL in dark and light teal for GP 1 and GP 2 , respectively) are shown at left. The electrostatic surface potential is shown at right. (B) Modeling suggests that K510E, an escape mutant of ADI-15946, clashes with CDR H3 and introduces conflicting negative charge into the CDR H3 pocket. (C) Electrostatic surface potential generated using the APBS plugin with Pymol. The surface of GP CL is shown on the left with the epitope outlined in black. The surface of ADI-15946 is shown on the right with the paratope outlined in black. All electrostatic surfaces are displayed with the same coloring as depicted in the included scale. Figure S3 . Comparison of the epitopes of ADI-15946 and monospecific base binders. In grey at left is a molecular surface of GP CL . Colored surfaces represent the respective footprints of ADI-15946 (orange), KZ52 (pink), and c4G7 (cyan). Next to each footprint is a partial amino acid sequence alignment of EBOV, SUDV, BDBV, TAFV and RESTV, with contact residues of each antibody highlighted in the appropriate color (ADI-15946 contacts are orange, KZ52 contacts are pink, etc.). Within each footprint, white inverted triangles indicate those contact residues that are similar across the ebolaviruses, while blue inverted triangles indicate those contact residues that differ more significantly across the ebolaviruses. Residues not indicated by triangles are either identical across the genus or not involved in the interface. Figure S4 . ADI-15946 CDR H3 binds to the 3 10 pocket and may inhibit conformational rearrangements of the 3 10 helix in the NPC1 bound complex. (A) ADI-15946 (orange) binds the 3 10 pocket of GP that is usually occupied by the β17-β18 loop of the glycan cap (teal). (B) (C) Binding to NPC1 loop C (pink) induces a conformational change in GP: the 3 10 helix unwinds and asparagine 73 (N73) becomes solvent exposed while lysine 510 (K510) inserts into the cavity left behind after the unwinding of the 3 10 helix. ADI-15946 may prevent these conformational changes from occurring by locking down the 3 10 helix with residues that mimic those of the β17-β18 loop. (D) Enlarged stereo view of ADI-15946 CDR H3 bound to the 3 10 pocket showing interactions between CDR H3 sidechains and residues of the 3 10 helix. The W291R mutation, modeled in yellow, introduces charge/steric clashes with EBOV GP 2 N512 (shown as a red surface). The Arg residue was modeled using the most common rotamer, but many other possible Arg rotamers also clash with neighboring residues in the 3 10 pocket. This mutation likely contributes to a decreased affinity of the β17-β18 loop for the 3 10 pocket. Figure S7 . FVM09 competition biolayer interferometry assays. EBOV GP was loaded onto Nickel-NTA biosensors followed by two association steps of test antibodies. Pre-binding of FVM09 does not interfere with subsequent association of ADI-15946 (A) or KZ52 (C). In a converse experiment, pre-binding of ADI-15946 (B) or KZ52 (D) to GP does not interfere with subsequent binding of FVM09. In the second association steps, the first binder is maintained at the same concentration as in the first association step with addition of the competing antibody. All measurements were performed with antibodies at 330 nM concentration. Figure S12. Ebolavirus conservation map and alignment. (A) Molecular surface of EBOV GP CL with the ADI-15946 footprint outlined in orange. GP residues conserved across the ebolaviruses are in grey. Similar residues are in white and residues that differ significantly are in blue. Differences at five sites (I-V) are listed at left. (B) Stereo view of the ADI-15946:GP CL interaction. GP is shown as a molecular surface and the interacting mAb residues are shown as sidechain residues along a ribbon backbone for clarity. The light chain is shown in light orange and the heavy chain is shown in darker orange. (C) Sequence alignment of GP from the five ebolaviruses, colored by conservation as in (A).
Figure S13. Neutralization of rVSVs bearing ebolavirus GPs by engineered variants of mAb ADI-15946. (A-E) Neutralization of rVSV bearing GP from EBOV, BDBV, SUDV, TAFV, and RESTV respectively. Wild-type ADI-15946 is in black, structure-guided mutants 46M1, 46M2 and 46M3 in light, medium and dark blue, respectively. (F-H) Neutralization of rVSV bearing GP CL from EBOV, BDBV and SUDV, respectively. Neutralization of GP CL -bearing virions by wild-type ADI-15946 is in orange. Mutants 46M1-46M3 are in light to dark blue. Neutralization of virions bearing full-length GP by wild-type ADI-15946 is shown in black for comparison. Figure S14 . The R100A mutation in CDR H3 enhances ADI-15946 binding to SUDV GP ecto . Antibody variants were tested for binding to soluble EBOV (A), BDBV (B), or SUDV (C) GP ectodomain immobilized on ELISA plates. 
